

GYKI-47261 dihydrochloride Biochemical | GYKI-47261 biochemical

GYKI-47261 dihydrochloride

CATALOG #
AAA227520


PRODUCT SYNONYMS

GYKI-47261 dihydrochloride; GYKI-47261 biochemical


PRODUCT SPECIFICATIONS

Purity/Purification	98%
CAS	1217049-32-5
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
In vitro	GYKI-47261 dihydrochloride (6 mg/kg; i.v.) shows antiischemic effect in a transient focal ischemia model, in rats. GYKI-47261 dihydrochloride (p.o.) potently mitigated the tremor induced by oxotremorine with ED50 of 16.8mg/kg in male CD1 mice[1]. GYKI-47261 dihydrochloride(20 mg/kg; i.p.) reverses the dopamine depleting effect of MPTP[1]. Animal Model: Male C57 black mice, weighing 23-30 g[1]. Dosage: 20 mg/kg. Administration: I.p. Result: Reversed the MPTP-induced decrease in striatal concentrations.
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure
CETP-IN-4, CAS 1648889-70-6



Structure
CETP-IN-4, CAS 1648889-70-6

ADDITIONAL INFORMATION

Related Product Information for GYKI-47261 biochemical	GYKI-47261 dihydrochloride is a competitive, orally active, and selective AMPA receptor antagonist with an IC 50 of 2.5 uM. GYKI-47261 has broad spectrum anticonvulsive activity and neuroprotective effects. GYKI-47261 dihydrochloride is also a potent inducer of CYP2E1.
References	1. Liu J, et al. Cholesteryl ester transfer protein (CETP) inhibitors based on cyclic urea, bicyclic urea and bicyclic sulfamide cores. Bioorg Med Chem Lett. 2021 Jan 15;32:127668.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

